{"id":132,"date":"2023-10-27T13:20:58","date_gmt":"2023-10-27T12:20:58","guid":{"rendered":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/?page_id=132"},"modified":"2026-01-26T14:11:25","modified_gmt":"2026-01-26T14:11:25","slug":"at1","status":"publish","type":"page","link":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/research\/chemical-probes\/at1\/","title":{"rendered":"AT1"},"content":{"rendered":"<div class=\"panel \">\n<figure class=\"wp-block-image size-large\"><source class=\"lazyload\" srcset=\"https:\/\/sites.dundee.ac.uk\/wp-content\/uploads\/sites\/233\/2023\/10\/AT1-copy.webp\" alt=\"AT1\" type=\"image\/webp\"><source class=\"lazyload\" srcset=\"https:\/\/sites.dundee.ac.uk\/wp-content\/uploads\/sites\/233\/2023\/10\/AT1-copy.jpg\" alt=\"AT1\" type=\"image\/jpeg\"><img decoding=\"async\" src=\"https:\/\/sites.dundee.ac.uk\/wp-content\/uploads\/sites\/233\/2023\/10\/AT1-copy.jpg\" alt=\"AT1\"><br \/>\n  <\/source><\/source><\/figure>\n<p class=\"media__annotation \">AT1<\/p>\n<p><strong>Protein Target(s) Name<\/strong>: BET protein BRD4<\/p>\n<p><strong>Mechanism of Action<\/strong>: PROTAC degrader<\/p>\n<p><strong>Description<\/strong>: VHL ligand based and (+)-JQ1 based PROTAC that selectively degrades BET protein Brd4 in cells, with negligible depletion of Brd2 or Brd3. AT1 was designed based on the ternary complex crystal structure of MZ1 (<em>1<\/em>).<\/p>\n<p><strong>Chemical Name<\/strong>: (2<em>S<\/em>,4<em>R<\/em>)-1-((<em>R<\/em>)-2-acetamido-3-((6-(2-((<em>S<\/em>)-4-(4-chlorophenyl)-2,3,9-trimethyl-6<em>H<\/em>-thieno[3,2-<em>f<\/em>][1,2,4]triazolo[4,3-<em>a<\/em>][1,4]diazepin-6-yl)acetamido)hexyl)thio)-3-methylbutanoyl)-4-hydroxy-<em>N<\/em>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide<\/p>\n<p><strong>CAS Number<\/strong>: 2098836-45-2<\/p>\n<p><strong>In vitro pharmacology*:<\/strong>\u00a0AT1 reduces Brd4 protein levels in human cells: Brd4 DC50 between 30-100 nM in HeLa cells (24 h); Dmax &gt; 95%.\u00a0Data from ref. (<em>1<\/em>)<br \/>\nAT1 shows antiproliferative and Myc-suppression activity in AML: pEC50 in MV4;11 cells (48 h) = 5.9 (unpublished data)<\/p>\n<p>*DC50: concentration in molar causing 50% reduction of protein level relative to vehicle control treatment.<br \/>\nDmax: maximum reduction of protein level relative to vehicle control treatment.<br \/>\nEC50: effective concentration in molar causing 50% reduction of cell viability relative to vehicle control treatment.<\/p>\n<p><strong>Biophysical binding data<\/strong>: ITC binary Kd (Brd4-BD2) = 45 nM;\u00a0ITC binary Kd (VHL) = 335 nM; ITC ternary Kd (VHL, in the presence of Brd4-BD2) = 47 nM; cooperativity (alpha) = 7. Ternary complex stability DeltaG =\u00a0-21.2 kcal\/mol.\u00a0Data from ref. (<em>1<\/em>)<br \/>\nTernary complex VHL:AT1:Brd4-BD2 t1\/2 (SPR) = 26 s. Data from ref. (<em>2<\/em>)<\/p>\n<p><strong>Proteome-wide selectivity<\/strong>:\u00a0Unbiased and quantitative isobaric tagging MS proteomics confirmed Brd4 as the sole protein markedly depleted (to ~40%) upon treatment of HeLa cells with AT1 (1 uM for 24 h) amongst the 5,674 detected proteins that passed filtering criteria, with negligible loss of Brd2 or Brd3. Data from ref. (<em>1<\/em>)<\/p>\n<p><strong>In vivo PK data<\/strong>: not available<\/p>\n<p><strong>Crystal Structure<\/strong>: not available<\/p>\n<p><strong>Negative control<\/strong>: not available<\/p>\n<div><\/div>\n<p><strong>Primary References:\u00a0<\/strong><\/p>\n<ol>\n<li>Gadd et al. (<strong>2017<\/strong>) Structural basis of PROTAC cooperative recognition for selective protein degradation.\u00a0<em>Nat. Chem. Biol.<\/em>\u00a0<em>13<\/em>, 514.\u00a0 DOI:\u00a0<a href=\"https:\/\/doi.org\/10.1038\/nchembio.2329\">10.1038\/nchembio.2329<\/a>; PMID:\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28288108\/\">28288108<\/a><\/li>\n<li>Roy et al. (<strong>2019<\/strong>) SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate.\u00a0<em>ACS Chem. Biol.<\/em>\u00a0<em>14<\/em>, 361. DOI:\u00a0<a href=\"https:\/\/doi.org\/10.1021\/acschembio.9b00092\">10.1021\/acschembio.9b00092<\/a>; PMID:\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30721025\/\">30721025<\/a><\/li>\n<\/ol>\n<p>\u00a0<\/p>\n<p><strong>Articles that have used AT1<\/strong>:<\/p>\n<ol>\n<li>2017 Gadd Nat Chem Biol\u00a0<a href=\"http:\/\/dx.doi.org\/10.1038\/nchembio.2329\">http:\/\/dx.doi.org\/10.1038\/nchembio.2329<\/a><\/li>\n<li>2019 Roy ACS Chem Biol\u00a0<a href=\"http:\/\/dx.doi.org\/10.1021\/acschembio.9b00092\">http:\/\/dx.doi.org\/10.1021\/acschembio.9b00092<\/a><\/li>\n<li>2020 Beveridge ACS Cent Sci\u00a0<a href=\"https:\/\/doi.org\/10.1021\/acscentsci.0c00049\">https:\/\/doi.org\/10.1021\/acscentsci.0c00049<\/a><\/li>\n<li>2020 Klein ACS Med Chem Lett\u00a0<a href=\"https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00265\">https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00265<\/a><\/li>\n<li>2022 Trapotsi ACS Chem Biol\u00a0<a href=\"https:\/\/doi.org\/10.1021\/acschembio.2c00076\">https:\/\/doi.org\/10.1021\/acschembio.2c00076<\/a><\/li>\n<li>2023 Hales Chemistry\u00a0<a href=\"https:\/\/doi.org\/10.1002\/chem.202301975\">https:\/\/doi.org\/10.1002\/chem.202301975<\/a><\/li>\n<\/ol>\n<h2>More information<\/h2>\n<p>More information on our chemical probes can be found from the\u00a0<a href=\"http:\/\/www.chemicalprobes.org\/\">Chemical Probes portal<\/a>, and from commercial vendors such as\u00a0<a href=\"https:\/\/www.tocris.com\/\">Tocris Bio-Techne<\/a>.<\/p>\n<h3>Related links<\/h3>\n<ul>\n<li class=\"field-item even\"><a href=\"https:\/\/www.tocris.com\/products\/at-1_6356\" target=\"_blank\" rel=\"noopener\">Tocris Biotechne: AT 1 Cat. No. 6356<\/a><\/li>\n<li class=\"field-item odd\"><a href=\"https:\/\/www.chemicalprobes.org\/at1\" target=\"_blank\" rel=\"noopener\">Chemical Probes.org: AT1<\/a><\/li>\n<li class=\"field-item even\"><a href=\"https:\/\/www.medchemexpress.com\/BRD4_degrader_AT1.html\" target=\"_blank\" rel=\"noopener\">MedChemExpress: AT1 Cat. No. HY-111433<\/a><\/li>\n<li class=\"field-item odd\"><a href=\"https:\/\/www.invivochem.com\/brd4-degrader-at1.html\" target=\"_blank\" rel=\"noopener\">InvivoChem: AT1 Cat #: V3581<\/a><\/li>\n<li class=\"field-item even\"><a href=\"http:\/\/www.dcchemicals.com\/product_show-DC10997.html\" target=\"_blank\" rel=\"noopener\">DC chemicals: AT1 Cat. No.: DC10997<\/a><\/li>\n<li class=\"field-item odd\"><a href=\"https:\/\/www.targetmol.com\/compound\/BRD4%20degrader%20AT1\" target=\"_blank\" rel=\"noopener\">TargetMol: AT1 Catalog No. T5439<\/a><\/li>\n<li class=\"field-item even\"><a href=\"https:\/\/protac.bocsci.com\/product\/at-1-cas-2098836-45-2-169850.html?nid=3051\" target=\"_blank\" rel=\"noopener\">Boc Sciences PROTAC: AT 1 \u2013 CAS 2098836-45-2<\/a><\/li>\n<li class=\"field-item odd\"><a href=\"https:\/\/www.glpbio.com\/brd4-degrader-at1.html\" target=\"_blank\" rel=\"noopener\">GLPBIO: AT1 Catalog No. GC33017<\/a><\/li>\n<li class=\"field-item even\"><a href=\"http:\/\/www.probechem.com\/products_BRD4degraderAT1.aspx\" target=\"_blank\" rel=\"noopener\">ProbeChem: AT1 Catalog No.: PC-35351<\/a><\/li>\n<\/ul>\n<p>\u00a0<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AT1 Protein Target(s) Name: BET protein BRD4 Mechanism of Action: PROTAC degrader Description: VHL ligand based and (+)-JQ1 based PROTAC that selectively degrades BET protein Brd4 in cells, with negligible depletion of Brd2 or Brd3. AT1 was designed based on the ternary complex crystal structure of MZ1 (1). Chemical Name: (2S,4R)-1-((R)-2-acetamido-3-((6-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)hexyl)thio)-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide CAS Number: 2098836-45-2 In [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":105,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-132","page","type-page","status-publish","hentry"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/wp-json\/wp\/v2\/pages\/132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/wp-json\/wp\/v2\/comments?post=132"}],"version-history":[{"count":2,"href":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/wp-json\/wp\/v2\/pages\/132\/revisions"}],"predecessor-version":[{"id":4405,"href":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/wp-json\/wp\/v2\/pages\/132\/revisions\/4405"}],"up":[{"embeddable":true,"href":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/wp-json\/wp\/v2\/pages\/105"}],"wp:attachment":[{"href":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/wp-json\/wp\/v2\/media?parent=132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}